Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 06, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in their interests in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to executive compensation and share transaction details.
Material Changes and Transactions
- Dr. J-P Garnier: Exercised options on 144,967 ADSs on August 3 and 80,357 ADSs on August 6. These options were granted in 1997 at an exercise price of $40.54 per ADS.
- Sold 144,967 ADSs on August 3 at an average price of $52.12 per ADS.
- Sold 80,357 ADSs on August 6 at an average price of $52.00 per ADS.
- Post-transaction total holding: 505,824 ADSs (including 247,016 deferred ADSs).
- Total holding value is equivalent to more than 14 times his annual basic salary.
- Mr. D Stout: Exercised options on 17,525 ADSs on August 3, granted in 1997 at an exercise price of $40.54 per ADS.
- Sold 15,240 ADSs on August 3 at an average price of $51.80 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly reports on compliance with Disclosure and Transparency Rules regarding director share transactions.
Investor Verification Points
- Verify the current market price of GSK ADSs to assess the realized gains from the August 2007 transactions.
- Confirm the total outstanding share count and the percentage of ownership held by Dr. Garnier and Mr. Stout post-transaction.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting and expiration conditions for these specific grants.